01177 Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

0 Analyst Rating

Wall Street analysts forecast 01177 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01177 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

0 Hold

0 Sell

Current: 6.440

Low

Averages

High

Current: 6.440

Low

Averages

High

G Sachs

Neutral

maintain

$63.3

2025-11-11

Reason

G Sachs

Price Target

$63.3

2025-11-11

maintain

Neutral

Reason

The article provides a list of stocks with their current prices, short selling data, and analyst ratings. All the listed stocks have a "Buy" rating, indicating that analysts believe these stocks are a good investment opportunity. The reasons for the "Buy" ratings are not explicitly stated in the provided text, but the presence of short selling data and the ratios may suggest that analysts see potential for price recovery or growth despite current short selling pressures. Additionally, the mention of "Order Momentum Remains Strong" for WUXI XDC implies that there is positive sentiment regarding its future performance, even though it has a neutral rating from G Sachs.

Guotai Junan

Buy

initiated

HKD10

2025-09-30

Reason

Guotai Junan

Price Target

HKD10

2025-09-30

initiated

Buy

Reason

The analyst rating from Guotai Junan for SINO BIOPHARM is a Buy, with a target price of HKD10. The reasons for this rating include: 1. Enhanced Innovation Capabilities: SINO BIOPHARM has improved its ability to innovate, which positions it well in the competitive healthcare sector. 2. Global Layout: The company has established a global presence, which can enhance its market opportunities and growth potential. 3. Improved Capital Market Sentiment: There has been a rebound in investment sentiment within China's healthcare sector, benefiting companies like SINO BIOPHARM. 4. Strong Market Position: As one of China's largest and most well-developed drug makers, SINO BIOPHARM has significant scale, financing capabilities, and commercial infrastructure. 5. Acquisition Potential: The company is well-positioned to acquire promising local biotech firms, which can accelerate the development and commercialization of new assets. These factors collectively contribute to a positive outlook for the company's earnings and growth prospects in the coming years.

BOCI

Buy

maintain

2025-08-20

Reason

BOCI

Price Target

2025-08-20

maintain

Buy

Reason

BOCOMI

Buy

maintain

2025-08-20

Reason

BOCOMI

Price Target

2025-08-20

maintain

Buy

Reason

Nomura

Buy

maintain

2025-08-19

Reason

Nomura

Price Target

2025-08-19

maintain

Buy

Reason

Citi

Buy

upgrade

2025-08-19

Reason

Citi

Price Target

2025-08-19

upgrade

Buy

Reason

The analyst rating for SINO BIOPHARM was upgraded to a Buy by Citi due to several positive factors highlighted in their research report. These include: 1. Strong Financial Performance: The company's 1H25 profit and turnover exceeded expectations, with a notable 27% year-over-year growth in sales of innovative products, reaching RMB7.8 billion. 2. Positive Sales Outlook: Management projects a continued 25% year-over-year increase in sales of innovative products for FY25, maintaining a double-digit growth target for both revenue and net profit. 3. New Product Pipeline: The expectation of over 19 new product approvals in the next three years, many of which have significant sales potential exceeding RMB2 billion, indicates strong future growth prospects. 4. Out-licensing Potential: There is confidence in the out-licensing potential of innovative candidate formulations, which adds to the company's growth opportunities. These factors led Citi to raise its target price for SINO BIOPHARM from HKD8.8 to HKD10.5, reflecting a positive outlook on the company's future performance.

Valuation Metrics

The current forward P/E ratio for SINO BIOPHARM (01177.HK) is 22.92, compared to its 5-year average forward P/E of 20.04. For a more detailed relative valuation and DCF analysis to assess SINO BIOPHARM 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

20.04

Current PE

22.92

Overvalued PE

25.55

Undervalued PE

14.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

10.76

Current EV/EBITDA

11.47

Overvalued EV/EBITDA

14.34

Undervalued EV/EBITDA

7.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.51

Current PS

3.05

Overvalued PS

3.42

Undervalued PS

1.59

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

01177 News & Events

Events Timeline

No data

News

4.5

12-15aastocks

HSI Closes Down 347 Points; Declines in Chip and Pharma Stocks; BIDU-SW Drops Approximately 6%

4.5

12-15aastocks

<Full-day Summary> HSI Falls 347 Points; HSTI Declines 139 Points; BABA Drops More Than 3%; PING AN, YOURAN DAIRY, FE HORIZON, LOGAN GROUP Reach New Peaks; Market Turnover Increases

4.5

12-15aastocks

HSI Declines 240 Points at Midday; BIDU-SW and KUAISHOU-W Show Weak Performance; Pharmaceutical Stocks Fall

People Also Watch

Frequently Asked Questions

What is SINO BIOPHARM (01177) stock price today?

The current price of 01177 is 6.44 USD — it has decreased -0.31 % in the last trading day.

What is SINO BIOPHARM (01177)'s business?

What is the price predicton of 01177 Stock?

Wall Street analysts forecast 01177 stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01177 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is SINO BIOPHARM (01177)'s revenue for the last quarter?

SINO BIOPHARM revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is SINO BIOPHARM (01177)'s earnings per share (EPS) for the last quarter?

SINO BIOPHARM. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for SINO BIOPHARM (01177)'s fundamentals?

The market is revising No Change the revenue expectations for 01177 for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by %.

How many employees does SINO BIOPHARM (01177). have?

SINO BIOPHARM (01177) has 0 emplpoyees as of December 17 2025.

What is SINO BIOPHARM (01177) market cap?

Today 01177 has the market capitalization of 0.00 USD.

01177

Overview

Forecast

Valuation

Earnings

01177

Overview

Forecast

Valuation

Earnings

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

01177 News & Events

Events Timeline

No data

News

People Also Watch

Frequently Asked Questions

What is SINO BIOPHARM (01177) stock price today?

What is SINO BIOPHARM (01177)'s business?

What is the price predicton of 01177 Stock?

What is SINO BIOPHARM (01177)'s revenue for the last quarter?

What is SINO BIOPHARM (01177)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for SINO BIOPHARM (01177)'s fundamentals?

How many employees does SINO BIOPHARM (01177). have?

What is SINO BIOPHARM (01177) market cap?